biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker KYTX. Primary therapeutic focus areas include Lupus Nephritis, Primary or Secondary Progressive Multiple Scl
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
KYV-101 anti-CD19 CAR-T cell therapy
Phase 2 · mab · Lupus Nephritis
KYV-101 anti-CD19 CAR-T cell therapy for Lupus Nephritis is a Phase 2 program (mab) at Kyverna Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code KYSA-3
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kyverna Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Lupus Nephritis
- Status
- active
- Trials
- 2